We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cyxone

News List

Cyxone Inks API Deal with European CDMO contractpharma
January 20, 2022
Takes next step in multiple sclerosis program engaging CDMO for production of drug candidate T20K.
Cyxone appoints Henrik Hang as CFO firstwordpharma
June 10, 2021
Cyxone AB (publ) (“Cyxone or the Company”) has appointed Henrik Hang as new CFO as of August 1st, 2021. Henrik has a degree in business administration and substantial experience from many years as CFO for international companies listed on First North Grow
Cyxone Explores Orphan Drug Designation for Rabeximod americanpharmaceuticalreview
September 09, 2019
Cyxone announced the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod.
Cyxone Submits First Application to Start Rabeximod Clinical Trial americanpharmaceuticalreview
July 08, 2019
Cyxone has submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of rheumatoid arthritis (RA).